|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] |
CTD |
PMID:18210232 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO EXP |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of BAD protein] arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BAD protein] |
CTD |
PMID:19682444 PMID:21420465 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2 protein] arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:19682444 PMID:21420465 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2L1 protein] |
CTD |
PMID:19682444 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of BID protein] |
CTD |
PMID:21420465 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
arjunolic acid inhibits the reaction [Acetaminophen results in increased cleavage of and results in increased activity of CASP3 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased activity of CASP3 protein] arjunolic acid inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein] |
CTD |
PMID:19133311 PMID:19682444 PMID:19922764 PMID:20053369 PMID:21420465 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein] |
CTD |
PMID:21420465 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased activity of CASP9 protein] |
CTD |
PMID:21420465 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; arjunolic acid inhibits the reaction [sodium arsenite affects the activity of CAT protein]; arjunolic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:18273903 PMID:18434106 PMID:19133311 PMID:19682444 PMID:20053369 PMID:21420465 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:21420465 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin affects the localization of CYCS protein] |
CTD |
PMID:19682444 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of FAS protein] |
CTD |
PMID:21420465 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] |
CTD |
PMID:19133311 PMID:19682444 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased activity of GSR protein]; arjunolic acid inhibits the reaction [sodium arsenite affects the activity of GSR protein]; arjunolic acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of GSR protein] |
CTD |
PMID:18273903 PMID:18434106 PMID:19682444 PMID:20053369 PMID:21420465 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of IFNG protein] |
CTD |
PMID:20053369 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:21420465 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of IL2 protein] |
CTD |
PMID:20053369 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
EXP |
Arjunolic acid promotes the reaction [Map3k7 protein binds to Ppara protein in cardiac fibroblasts] |
RGD |
PMID:28821620 |
RGD:155804266 |
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of NFKBIA protein] arjunolic acid inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20053369 PMID:21420465 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; arjunolic acid inhibits the reaction [Cisplatin results in increased expression of NOS2] |
CTD |
PMID:19922764 PMID:25130312 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression |
EXP |
arjunolic acid increases expression of Nr1h4 mRNA in steatotic liver |
RGD |
PMID:30257410 |
RGD:15090799 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:21420465 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of PRKCD protein] |
CTD |
PMID:19682444 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in increased expression of PRKCE protein] |
CTD |
PMID:19682444 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
arjunolic acid inhibits the reaction [Cadmium Chloride results in increased expression of RELA protein] arjunolic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; arjunolic acid inhibits the reaction [Streptozocin results in increased phosphorylation of RELA protein] |
CTD |
PMID:19133311 PMID:19682444 PMID:20053369 PMID:21420465 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of SOD1 protein] |
CTD |
PMID:20053369 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Streptozocin results in decreased activity of SOD2 protein] |
CTD |
PMID:20053369 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
arjunolic acid inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; arjunolic acid inhibits the reaction [Cisplatin results in increased expression of TNF]; arjunolic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein] |
CTD |
PMID:19682444 PMID:19922764 PMID:20053369 PMID:25130312 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of BAX protein] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BCL2 protein] asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP9 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYP2E1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3A protein] |
CTD |
PMID:34794910 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [cypermethrin results in decreased expression of DNMT3B protein] |
CTD |
PMID:34794910 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of and results in decreased secretion of GPX1 protein] |
CTD |
PMID:28004603 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of and results in decreased secretion of GSR protein] |
CTD |
PMID:28004603 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL1B protein] |
CTD |
PMID:30802477 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein] |
CTD |
PMID:30802477 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; asiatic acid inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:30802477 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]; asiatic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:30802477 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of NQO1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] |
CTD |
PMID:29108773 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of POR protein] |
CTD |
PMID:29108773 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[Glutamic Acid co-treated with asiatic acid] results in increased expression of PPARGC1A protein |
CTD |
PMID:22447225 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]] |
CTD |
PMID:30802477 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]] |
CTD |
PMID:30802477 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [cypermethrin results in decreased phosphorylation of SP1 protein] |
CTD |
PMID:34794910 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]] asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]] |
CTD |
PMID:30802477 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Hydrogen Peroxide results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 protein] |
CTD |
PMID:18802751 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32344236 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
ISO |
astragaloside A results in increased expression of AQP9 mRNA; astragaloside A results in increased expression of AQP9 protein |
CTD |
PMID:37918281 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:17509559 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein] |
CTD |
PMID:22278385 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein] |
CTD |
PMID:33285147 PMID:36322813 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein] |
CTD |
PMID:22278385 |
|
NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] |
CTD |
PMID:33285147 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:22278385 PMID:30842369 PMID:33285147 PMID:36322813 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
astragaloside A results in increased expression of CCND1 protein |
CTD |
PMID:37918281 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
decreases expression multiple interactions |
ISO |
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of GJA4 protein] |
CTD |
PMID:36322813 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein] |
CTD |
PMID:34434659 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein] |
CTD |
PMID:30842369 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
increases expression multiple interactions |
ISO |
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
Hdac9 |
histone deacetylase 9 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein] |
CTD |
PMID:36322813 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25604657 PMID:30842369 PMID:32344236 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Khdrbs1 |
KH RNA binding domain containing, signal transduction associated 1 |
decreases expression multiple interactions |
ISO |
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:142,051,844...142,089,175
Ensembl chr 5:142,063,570...142,089,180
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein |
CTD |
PMID:32344236 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] |
CTD |
PMID:25604657 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases phosphorylation |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta |
CTD RGD |
PMID:32344236 PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Muc5b |
mucin 5B, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein |
CTD |
PMID:25422538 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] |
CTD |
PMID:25604657 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
ISO |
astragaloside A results in increased expression of PCNA protein |
CTD |
PMID:37918281 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pln |
phospholamban |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein] |
CTD |
PMID:17509559 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases expression |
EXP |
Astragaloside IV increases expression of Ptpn1 protein in the hypothalamus |
RGD |
PMID:29562733 |
RGD:401976390 |
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rho |
rhodopsin |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773
|
|
G |
Rpe65 |
retinoid isomerohydrolase RPE65 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] |
CTD |
PMID:25604657 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:25604657 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein |
CTD |
PMID:32344236 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA] |
CTD |
PMID:29501766 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased cleavage of CASP3 protein]; beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of CASP3 mRNA] |
CTD |
PMID:27009110 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B protein]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 protein]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] |
CTD |
PMID:29501766 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL1B protein] |
CTD |
PMID:29501766 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL6 protein] |
CTD |
PMID:29501766 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:29501766 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA] |
CTD |
PMID:29501766 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] |
CTD |
PMID:18210232 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 protein] |
CTD |
PMID:27009110 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF mRNA]; beta-amyrin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] beta-amyrin inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF protein] |
CTD |
PMID:27009110 PMID:29501766 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
betulin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; betulin inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123] |
CTD |
PMID:33321149 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased expression of ACTA2 protein] |
CTD |
PMID:21172400 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AHR protein] |
CTD |
PMID:33759307 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
betulin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:32190974 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARNT protein] |
CTD |
PMID:33759307 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
betulin results in increased expression of BAX protein |
CTD |
PMID:33181113 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[betulin co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein |
CTD |
PMID:33181113 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
betulin analog promotes the reaction [Oxygen deficiency results in decreased expression of BIRC5 protein] betulin analog results in decreased expression of BIRC5 protein |
CTD |
PMID:26540049 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib] |
CTD |
PMID:29950559 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Car9 |
carbonic anhydrase 9 |
multiple interactions |
ISO |
betulin analog inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein] |
CTD |
PMID:26540049 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
betulin results in increased cleavage of CASP3 protein Chloroquine inhibits the reaction [betulin results in increased cleavage of CASP3 protein] |
CTD |
PMID:32190974 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
betulin results in increased cleavage of CASP8 protein |
CTD |
PMID:32190974 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
betulin results in increased cleavage of CASP9 protein |
CTD |
PMID:32190974 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein] |
CTD |
PMID:33759307 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[betulin co-treated with Oxygen deficiency] results in decreased expression of CTNNB1 protein |
CTD |
PMID:33181113 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein] |
CTD |
PMID:33759307 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases phosphorylation |
ISO |
[Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein betulin results in decreased phosphorylation of EGFR protein |
CTD |
PMID:27447558 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation |
ISO |
betulin results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:32190974 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
betulin results in decreased expression of FASN mRNA; betulin results in decreased expression of FASN protein |
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
betulin results in decreased expression of G6PC1 protein |
CTD |
PMID:34500009 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[betulin co-treated with Oxygen deficiency] affects the phosphorylation of GSK3B protein |
CTD |
PMID:33181113 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
betulin analog results in decreased expression of HIF1A protein; betulin results in decreased expression of HIF1A protein betulin analog inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] |
CTD |
PMID:26540049 PMID:33181113 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
betulin results in decreased expression of HMGCR mRNA; betulin results in decreased expression of HMGCR protein |
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
ISO |
betulin results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:27378817 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein] |
CTD |
PMID:33759307 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
increases secretion |
ISO |
betulin results in increased secretion of IFNG protein |
CTD |
PMID:25756279 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il12a |
interleukin 12A |
multiple interactions increases expression |
ISO |
betulin results in increased secretion of [IL12A protein binds to IL12B protein] betulin results in increased expression of IL12A mRNA |
CTD |
PMID:25756279 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
betulin results in increased secretion of [IL12A protein binds to IL12B protein] |
CTD |
PMID:25756279 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
betulin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:34500009 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases secretion |
ISO |
betulin results in increased secretion of IL2 protein |
CTD |
PMID:25756279 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein] |
CTD |
PMID:33759307 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
[betulin co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK1 protein betulin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:33181113 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
betulin results in increased phosphorylation of MAPK3 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK3 mRNA] [betulin co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:33181113 PMID:33759307 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK8 mRNA] |
CTD |
PMID:33759307 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Marveld1 |
MARVEL domain containing 1 |
decreases expression |
ISO |
betulin results in decreased expression of MARVELD1 mRNA |
CTD |
PMID:27447558 |
|
NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein |
CTD |
PMID:27447558 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased expression of MMP2 protein] |
CTD |
PMID:21172400 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
betulin results in decreased phosphorylation of MTOR protein |
CTD |
PMID:32190974 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[betulin co-treated with Oxygen deficiency] results in decreased expression of MYC protein |
CTD |
PMID:33181113 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein] |
CTD |
PMID:33759307 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
betulin binds to and affects the localization of NR3C1 protein |
CTD |
PMID:34500009 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[betulin co-treated with Oxygen] results in increased cleavage of PARP1 protein; betulin analog promotes the reaction [Oxygen deficiency results in increased expression of PARP1 protein modified form]; Chloroquine inhibits the reaction [betulin results in increased cleavage of PARP1 protein] |
CTD |
PMID:26540049 PMID:32190974 PMID:33181113 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
betulin results in increased expression of PCK1 protein |
CTD |
PMID:34500009 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein] |
CTD |
PMID:21172400 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
betulin results in decreased expression of SCD mRNA; betulin results in decreased expression of SCD protein |
CTD |
PMID:27378817 PMID:27447558 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:21172400 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases cleavage multiple interactions decreases expression |
ISO |
betulin results in decreased cleavage of SREBF1 protein [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]] betulin results in decreased expression of SREBF1 protein |
CTD |
PMID:27447558 PMID:29950559 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases sulfation |
ISO |
SULT2A1 protein results in increased sulfation of betulin |
CTD |
PMID:30776358 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] |
CTD |
PMID:21172400 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased expression of TIMP1 protein] |
CTD |
PMID:21172400 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
EXP |
betulin inhibits the reaction [Ethanol results in increased expression of TIMP2 protein] |
CTD |
PMID:21172400 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
betulin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:34500009 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of betulin |
CTD |
PMID:30776358 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of betulin |
CTD |
PMID:30776358 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]; Betulinic Acid inhibits the reaction [Thioacetamide results in increased expression of ACTA2] |
CTD |
PMID:21172400 PMID:22285267 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Betulinic Acid results in increased phosphorylation of AKT1 protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16077934 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression multiple interactions |
ISO |
Betulinic Acid results in increased expression of BAK1 protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased expression of BAK1 protein |
CTD |
PMID:33181113 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Betulinic Acid analog] results in increased activity of BAX protein; CA 074 methyl ester inhibits the reaction [[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Betulinic Acid analog] results in increased activity of BAX protein] |
CTD |
PMID:23000516 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Betulinic Acid results in decreased expression of BCL2 protein [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein |
CTD |
PMID:30136359 PMID:33181113 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases response to substance decreases expression increases expression |
ISO |
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased expression of BIRC5]; Betulinic Acid promotes the reaction [Oxygen deficiency results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein] BIRC5 protein results in decreased susceptibility to Betulinic Acid |
CTD |
PMID:16077934 PMID:26540049 PMID:30136359 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
increases expression decreases expression |
ISO |
Betulinic Acid results in increased expression of BMI1 protein Betulinic Acid results in decreased expression of BMI1 protein |
CTD |
PMID:33157086 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases activity multiple interactions |
ISO |
Betulinic Acid analog results in decreased activity of CA9 protein Betulinic Acid inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein] |
CTD |
PMID:26540049 PMID:29454615 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Betulinic Acid analog results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; CA 074 methyl ester inhibits the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Betulinic Acid analog results in increased cleavage of CASP3 protein]]; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP3 protein modified form] Betulinic Acid analog results in increased cleavage of CASP3 protein; Betulinic Acid results in increased cleavage of CASP3 protein Betulinic Acid analog results in increased activity of CASP3 protein; Betulinic Acid results in increased activity of CASP3 protein |
CTD |
PMID:22260869 PMID:23000516 PMID:26772157 PMID:28578903 PMID:29454615 PMID:30136359 PMID:30482226 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP7 protein modified form] Betulinic Acid results in increased activity of CASP7 protein |
CTD |
PMID:22260869 PMID:30136359 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Betulinic Acid results in increased activity of CASP8 protein |
CTD |
PMID:26772157 PMID:29454615 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Betulinic Acid analog results in increased activity of CASP9 protein; Betulinic Acid results in increased activity of CASP9 protein |
CTD |
PMID:26772157 PMID:29454615 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in decreased activity of CAT protein] |
CTD |
PMID:34472159 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Betulinic Acid results in decreased expression of CCNB1 protein |
CTD |
PMID:33181113 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Betulinic Acid analog results in decreased expression of CCND1 protein; Betulinic Acid results in decreased expression of CCND1 protein [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of CCND1 protein |
CTD |
PMID:28254521 PMID:33181113 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein] |
CTD |
PMID:30136359 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Betulinic Acid analog results in increased expression of CDKN1A protein |
CTD |
PMID:28254521 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions decreases expression |
ISO |
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] Betulinic Acid results in decreased expression of CEBPB protein modified form |
CTD |
PMID:30482226 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression |
ISO |
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein; [Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of CTNNB1 protein Betulinic Acid results in decreased expression of CTNNB1 protein |
CTD |
PMID:30136359 PMID:33181113 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of CTSK protein] |
CTD |
PMID:24463094 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] |
CTD |
PMID:30482226 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of EGFR protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form] |
CTD |
PMID:16077934 PMID:30136359 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
Betulinic Acid results in increased phosphorylation of GSK3B protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of GSK3B protein |
CTD |
PMID:33181113 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
Betulinic Acid results in decreased expression of HIF1A protein [Betulinic Acid co-treated with Oxygen deficiency] affects the expression of HIF1A protein |
CTD |
PMID:26540049 PMID:33181113 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[VDAC1 protein results in decreased susceptibility to Betulinic Acid] which results in increased expression of HK2 protein |
CTD |
PMID:30136359 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in increased expression of IL6 protein] |
CTD |
PMID:34472159 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:30136359 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of MAPK1 protein]; [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16077934 PMID:33181113 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Betulinic Acid results in increased phosphorylation of MAPK3 protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Betulinic Acid results in increased phosphorylation of MAPK3 protein]; [Betulinic Acid co-treated with Oxygen deficiency] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16077934 PMID:33181113 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir24-2 |
microRNA 24-2 |
multiple interactions affects response to substance |
ISO |
MIR24-2 mRNA affects the susceptibility to [Betulinic Acid co-treated with Gemcitabine] MIR24-2 mRNA affects the susceptibility to Betulinic Acid |
CTD |
PMID:25841339 |
|
NCBI chr19:23,954,683...23,954,790
Ensembl chr19:23,954,683...23,954,790
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of MMP2 protein] Betulinic Acid affects the reaction [TGFB1 protein affects the expression of and affects the secretion of MMP2 protein] Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP2 protein] |
CTD |
PMID:21172400 PMID:24463094 PMID:28578903 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP9 protein] |
CTD |
PMID:24463094 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Betulinic Acid co-treated with Oxygen deficiency] results in decreased expression of MYC protein |
CTD |
PMID:33181113 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21172400 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein] |
CTD |
PMID:30482226 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases expression |
ISO |
Betulinic Acid results in increased cleavage of PARP1 protein [Betulinic Acid co-treated with Oxygen] results in increased cleavage of PARP1 protein; Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein] Betulinic Acid results in increased expression of PARP1 protein modified form |
CTD |
PMID:26540049 PMID:30136359 PMID:33181113 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
EXP ISO |
Betulinic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] Betulinic Acid analog results in decreased expression of PCNA protein |
CTD |
PMID:28254521 PMID:34541749 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
affects binding |
ISO |
Betulinic Acid binds to PLA2G2A protein |
CTD |
PMID:29391000 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PTGS2 protein] |
CTD |
PMID:34541749 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
multiple interactions decreases response to substance decreases secretion decreases expression |
ISO |
Betulinic Acid inhibits the reaction [PTHLH protein results in increased expression of TNFSF11 protein] Betulinic Acid results in decreased susceptibility to PTHLH protein Betulinic Acid results in decreased secretion of PTHLH protein Betulinic Acid results in decreased expression of PTHLH mRNA |
CTD |
PMID:24463094 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions |
ISO |
Betulinic Acid results in decreased expression of RB1 protein modified form Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form] |
CTD |
PMID:30136359 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein] |
CTD |
PMID:21172400 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:21172400 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form |
CTD |
PMID:30136359 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] Betulinic Acid affects the reaction [TGFB1 protein affects the expression of and affects the secretion of MMP2 protein] |
CTD |
PMID:21172400 PMID:28578903 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TIMP1 protein] |
CTD |
PMID:21172400 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Ethanol results in increased expression of TIMP2 protein] |
CTD |
PMID:21172400 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Betulinic Acid inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF protein] |
CTD |
PMID:34472159 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases response to substance |
ISO |
Betulinic Acid inhibits the reaction [PTHLH protein results in increased expression of TNFSF11 protein] Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of CTSK protein]; Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP2 protein]; Betulinic Acid inhibits the reaction [TNFSF11 protein results in increased secretion of MMP9 protein] Betulinic Acid results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:24463094 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Betulinic Acid results in decreased activity of TOP1 protein |
CTD |
PMID:10860928 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases activity |
ISO |
Betulinic Acid results in decreased activity of TOP2A protein |
CTD |
PMID:10860928 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Betulinic Acid results in increased expression of TP53 protein [Betulinic Acid co-treated with Oxygen deficiency] results in increased expression of TP53 protein |
CTD |
PMID:33181113 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein] |
CTD |
PMID:30482226 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions decreases expression |
ISO |
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein] |
CTD |
PMID:30136359 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
decreases response to substance increases expression multiple interactions |
ISO |
VDAC1 protein results in decreased susceptibility to Betulinic Acid Betulinic Acid results in increased expression of VDAC1 protein [VDAC1 protein results in decreased susceptibility to Betulinic Acid] which results in increased expression of HK2 protein; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP3 protein modified form]; VDAC1 protein inhibits the reaction [Betulinic Acid results in increased expression of CASP7 protein modified form] |
CTD |
PMID:30136359 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Enzymes and Coenzymes inhibits the reaction [celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] |
CTD |
PMID:35101544 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
celastrol inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]; celastrol inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]; SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]] celastrol inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:29789558 PMID:31901889 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of ADGRE1 protein]; celastrol inhibits the reaction [Acetaminophen results in increased expression of ADGRE1 protein] |
CTD |
PMID:28435131 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Ahsa1 |
activator of Hsp90 ATPase activity 1 |
increases expression |
ISO |
celastrol results in increased expression of AHSA1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
celastrol results in increased expression of AKR1C1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
celastrol results in increased expression of AKR1C2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
celastrol results in decreased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of AKT1 protein] celastrol results in increased phosphorylation of AKT1 protein celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:21466843 PMID:24111524 PMID:25903958 PMID:31715269 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
multiple interactions |
ISO |
celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 protein]; celastrol affects the reaction [APC protein mutant form affects the expression of CTNNB1 protein]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC protein]; celastrol affects the reaction [APC protein mutant form affects the phosphorylation of GSK3B protein] |
CTD |
PMID:31715269 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression increases degradation |
ISO |
calpain inhibitor 2 inhibits the reaction [celastrol results in increased degradation of AR protein]; CAST inhibits the reaction [celastrol results in increased degradation of AR protein] celastrol results in decreased expression of AR protein |
CTD |
PMID:17010675 PMID:18726991 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
celastrol results in decreased expression of ARID5B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[celastrol co-treated with CNR2 protein] affects the localization of ARRB2 protein |
CTD |
PMID:31901889 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
celastrol results in increased expression of ATF3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of ATP5MC1 mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
|
|
G |
Axin2 |
axin 2 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein] |
CTD |
PMID:31715269 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
ISO |
celastrol results in increased expression of BAG3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of BAX mRNA; celastrol results in increased expression of BAX protein Uridine inhibits the reaction [celastrol results in increased expression of BAX protein] [celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; celastrol inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; celastrol inhibits the reaction [Plant Preparations results in increased expression of BAX mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of BAX protein] |
CTD |
PMID:21466843 PMID:27374097 PMID:28435131 PMID:29643811 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions increases expression |
ISO |
celastrol results in decreased expression of BCL2 protein celastrol inhibits the reaction [Plant Preparations results in decreased expression of BCL2 protein] celastrol results in increased expression of BCL2 mRNA |
CTD |
PMID:21466843 PMID:29643811 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in increased expression of BDNF protein] |
CTD |
PMID:35679966 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression |
EXP |
celastrol results in increased expression of BECN1 protein |
CTD |
PMID:32470352 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
celastrol results in decreased expression of BIRC5 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
celastrol results in decreased expression of BTG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Cacybp |
calcyclin binding protein |
increases expression |
ISO |
celastrol results in increased expression of CACYBP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]] |
CTD |
PMID:32470352 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression |
ISO EXP |
celastrol results in increased cleavage of CASP3 protein celastrol inhibits the reaction [Plant Preparations results in increased expression of CASP3 mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of CASP3 protein] celastrol results in increased expression of CASP3 mRNA celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; JUN mutant form promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]] [TNFSF10 protein co-treated with celastrol] results in increased cleavage of CASP3 protein; Uridine inhibits the reaction [celastrol results in increased cleavage of CASP3 protein] |
CTD |
PMID:20605676 PMID:21466843 PMID:24111524 PMID:27374097 PMID:29643811 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage decreases expression |
ISO |
celastrol results in increased cleavage of CASP8 protein celastrol results in decreased expression of CASP8 mRNA |
CTD |
PMID:21466843 PMID:27374097 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage increases expression multiple interactions |
ISO |
celastrol results in increased cleavage of CASP9 protein celastrol results in increased expression of CASP9 mRNA Uridine inhibits the reaction [celastrol results in increased cleavage of CASP9 protein] |
CTD |
PMID:21466843 PMID:27374097 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
CAST inhibits the reaction [celastrol results in increased degradation of AR protein] |
CTD |
PMID:18726991 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
celastrol inhibits the reaction [Bleomycin results in decreased activity of CAT protein] celastrol inhibits the reaction [Acetaminophen results in decreased activity of CAT protein] |
CTD |
PMID:26768587 PMID:28984147 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
celastrol results in increased expression of CBR3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
celastrol results in increased expression of CCL3 mRNA |
CTD |
PMID:25477506 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of CCND1 protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein] celastrol results in decreased expression of CCND1 mRNA; celastrol results in decreased expression of CCND1 protein |
CTD |
PMID:31715269 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cda |
cytidine deaminase |
increases expression |
ISO |
celastrol results in increased expression of CDA mRNA |
CTD |
PMID:27374097 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
G |
Cdc7 |
cell division cycle 7 |
decreases expression |
ISO |
celastrol results in decreased expression of CDC7 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr14:2,804,660...2,824,796
Ensembl chr14:2,804,661...2,824,778
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
celastrol results in decreased expression of CDK2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
affects expression |
ISO |
celastrol affects the expression of CEBPA mRNA; celastrol affects the expression of CEBPA protein |
CTD |
PMID:27085773 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
celastrol results in increased expression of CHORDC1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased phosphorylation of CHUK protein] |
CTD |
PMID:30588110 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
ISO |
celastrol results in decreased expression of CITED2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:30588110 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:30588110 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
[celastrol co-treated with CNR2 protein] affects the localization of ARRB2 protein; celastrol inhibits the reaction [TGFB1 protein results in decreased expression of CNR2 protein] 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in decreased expression of CNR2 protein]]; celastrol inhibits the reaction [Folic Acid results in decreased expression of CNR2 protein] |
CTD |
PMID:29789558 PMID:31901889 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased expression of COL1A1 mRNA] |
CTD |
PMID:30588110 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
ISO |
celastrol results in increased expression of CRYAB mRNA |
CTD |
PMID:25477506 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in increased expression of CS mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
ISO |
celastrol results in decreased expression of CTNNB1 protein celastrol affects the reaction [APC protein mutant form affects the expression of CTNNB1 protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased expression of CTNNB1 protein]; Chir 99021 inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]; GSK3B protein affects the reaction [celastrol results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein]; SB 216763 inhibits the reaction [celastrol results in decreased expression of CTNNB1 protein] |
CTD |
PMID:31715269 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of CXCL10 mRNA celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] |
CTD |
PMID:25477506 PMID:31901889 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Celastrol decreases expression of CXCR4 mRNA and protein in liver |
RGD |
PMID:33574707 |
RGD:151665327 |
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases expression |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of CYCS mRNA] celastrol results in increased expression of CYCS mRNA |
CTD |
PMID:35679966 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression |
ISO |
celastrol results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
celastrol results in increased expression of DDIT3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
celastrol results in increased expression of DDIT4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
decreases expression |
ISO |
celastrol results in decreased expression of DHODH mRNA; celastrol results in decreased expression of DHODH protein |
CTD |
PMID:27374097 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
increases expression |
ISO |
celastrol results in increased expression of DNAJA1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
celastrol results in increased expression of DNAJB4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Efnb2 |
ephrin B2 |
decreases expression |
ISO |
celastrol results in decreased expression of EFNB2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO |
[Sulfasalazine co-treated with celastrol] affects the expression of EGFR protein; [Sulfasalazine co-treated with celastrol] results in decreased expression of EGFR protein celastrol results in decreased expression of EGFR protein |
CTD |
PMID:17010675 PMID:20007406 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:24111524 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
affects expression |
ISO |
celastrol affects the expression of FABP4 mRNA |
CTD |
PMID:27085773 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
celastrol results in increased expression of FAS protein |
CTD |
PMID:21466843 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
celastrol results in increased expression of FASLG protein |
CTD |
PMID:21466843 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions decreases expression |
EXP |
HSPA1A protein affects the reaction [celastrol results in decreased expression of FBXO32 protein] |
CTD |
PMID:25903958 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Ficd |
FIC domain protein adenylyltransferase |
increases expression |
ISO |
celastrol results in increased expression of FICD mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:42,889,195...42,894,090
Ensembl chr12:42,889,194...42,894,070
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression |
ISO |
celastrol results in decreased expression of FLT3 protein |
CTD |
PMID:17010675 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO EXP |
celastrol inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of FN1 mRNA] celastrol inhibits the reaction [Folic Acid results in increased expression of FN1 protein]; SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of FN1 protein]] |
CTD |
PMID:29789558 PMID:30588110 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo3 |
forkhead box O3 |
increases phosphorylation |
EXP |
celastrol results in increased phosphorylation of FOXO3 protein |
CTD |
PMID:25903958 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of GAPDH mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gatd3a |
glutamine amidotransferase class 1 domain containing 3A |
decreases expression |
ISO |
celastrol results in decreased expression of GATD3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLC mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLC protein] |
CTD |
PMID:30588110 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO EXP |
celastrol results in increased expression of GCLM mRNA celastrol inhibits the reaction [Doxorubicin results in decreased expression of GCLM mRNA] |
CTD |
PMID:17010675 PMID:30588110 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
celastrol results in increased expression of GDF15 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
affects activity |
ISO |
celastrol affects the activity of GPD1 protein |
CTD |
PMID:27085773 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[coomassie Brilliant Blue co-treated with celastrol] inhibits the reaction [Acetaminophen results in increased activity of GPT protein]; celastrol inhibits the reaction [Acetaminophen results in increased activity of GPT protein]; celastrol inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:28435131 PMID:35679966 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation multiple interactions |
ISO |
celastrol results in decreased phosphorylation of GSK3B protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of GSK3B protein]; GSK3B protein affects the reaction [celastrol results in decreased expression of CTNNB1 protein]; Lithium Chloride inhibits the reaction [celastrol results in decreased phosphorylation of GSK3B protein] celastrol affects the reaction [APC protein mutant form affects the phosphorylation of GSK3B protein] |
CTD |
PMID:31715269 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
celastrol inhibits the reaction [Bleomycin results in decreased activity of GSR protein] celastrol inhibits the reaction [Acetaminophen results in decreased activity of GSR protein] |
CTD |
PMID:26768587 PMID:28984147 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
increases expression |
ISO |
celastrol results in increased expression of GTPBP2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
decreases expression |
ISO |
celastrol results in decreased expression of HILPDA mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of HK2 mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
celastrol results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
celastrol results in increased expression of HMOX1 mRNA celastrol inhibits the reaction [Plant Preparations results in decreased expression of HMOX1 mRNA]; celastrol inhibits the reaction [Plant Preparations results in decreased expression of HMOX1 protein] celastrol results in increased expression of HMOX1 protein celastrol inhibits the reaction [Bleomycin results in decreased expression of HMOX1 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein] |
CTD |
PMID:17010675 PMID:23942037 PMID:26768587 PMID:29643811 PMID:30588110 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions increases activity |
EXP ISO |
celastrol results in increased phosphorylation of and affects the localization of HSF1 protein celastrol results in increased activity of HSF1 protein |
CTD |
PMID:25903958 PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases activity multiple interactions |
ISO EXP |
celastrol results in decreased activity of HSP90AA1 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA] |
CTD |
PMID:17010675 PMID:32470352 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein] |
CTD |
PMID:32470352 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa13 |
heat shock protein family A (Hsp70) member 13 |
increases expression |
ISO |
celastrol results in increased expression of HSPA13 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression multiple interactions |
ISO EXP |
celastrol results in increased expression of HSPA1A mRNA HSPA1A protein affects the reaction [celastrol results in decreased expression of FBXO32 protein] |
CTD |
PMID:17010675 PMID:25477506 PMID:25903958 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
celastrol results in increased expression of HSPA1B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
celastrol results in increased expression of HSPA5 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
increases expression |
ISO |
celastrol results in increased expression of HSPA6 mRNA |
CTD |
PMID:25477506 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
celastrol results in increased expression of HSPH1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:16769766 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of IDH1 mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
celastrol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IFNG protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein] |
CTD |
PMID:16769766 PMID:24384223 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL10 protein]; celastrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein] |
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL17A protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein] |
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]] |
CTD |
PMID:32470352 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
celastrol inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of SELE protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]] celastrol results in increased expression of IL1B mRNA celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of IL1B protein] |
CTD |
PMID:16769766 PMID:24384223 PMID:25477506 PMID:29643811 PMID:31715269 PMID:31901889 PMID:32470352 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
ISO |
celastrol results in decreased expression of IL1RN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL23A protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein] |
CTD |
PMID:24384223 PMID:28435131 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
celastrol results in increased expression of IL6 mRNA celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; celastrol inhibits the reaction [Plant Preparations results in increased expression of IL6 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of IL6 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:25477506 PMID:29643811 PMID:30588110 PMID:31715269 PMID:32470352 PMID:35679966 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the oxidation of Glucose]; celastrol affects the reaction [[Dietary Fats affects the susceptibility to INS1 protein] which affects the uptake of Glucose]; celastrol inhibits the reaction [Dietary Fats results in increased expression of INS1 protein] |
CTD |
PMID:35679966 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
celastrol results in increased expression of INSIG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
celastrol results in decreased expression of JAG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]; JUN mutant form promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]] |
CTD |
PMID:24111524 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
ISO |
celastrol results in decreased expression of KCNN2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Bleomycin results in decreased expression of KEAP1 protein] |
CTD |
PMID:26768587 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
celastrol results in increased expression of LDLR mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein] |
CTD |
PMID:31715269 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
celastrol results in increased expression of LPIN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Ltn1 |
listerin E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
celastrol results in decreased expression of LTN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:26,603,903...26,660,871
Ensembl chr11:26,603,903...26,660,886
|
|
G |
Mafb |
MAF bZIP transcription factor B |
decreases expression |
ISO |
celastrol results in decreased expression of MAFB mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
celastrol promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein] celastrol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24111524 PMID:25903958 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
celastrol promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein] celastrol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24111524 PMID:25903958 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
decreases expression |
ISO |
celastrol results in decreased expression of MDH2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
celastrol results in increased expression of ME1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Bleomycin results in increased expression of MMP2 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] |
CTD |
PMID:26768587 PMID:30588110 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Bleomycin results in increased expression of MMP9 protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of MMP9 protein] |
CTD |
PMID:26768587 PMID:30588110 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnt |
MAX network transcriptional repressor |
increases expression |
ISO |
celastrol results in increased expression of MNT mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:59,699,208...59,714,848
Ensembl chr10:59,699,585...59,714,835
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO EXP |
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased activity of MPO protein]; celastrol inhibits the reaction [Acetaminophen results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein] |
CTD |
PMID:24384223 PMID:28435131 PMID:32470352 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrpl18 |
mitochondrial ribosomal protein L18 |
increases expression |
ISO |
celastrol results in increased expression of MRPL18 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:47,837,169...47,841,987
Ensembl chr 1:47,836,561...47,841,987
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
celastrol results in decreased expression of MSH6 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
celastrol results in increased expression of MSMO1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with celastrol] results in decreased expression of MTOR protein modified form; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein modified form] |
CTD |
PMID:32470352 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
celastrol results in decreased expression of MYC mRNA; celastrol results in decreased expression of MYC protein celastrol affects the reaction [APC protein mutant form affects the expression of MYC mRNA]; celastrol affects the reaction [APC protein mutant form affects the expression of MYC protein]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein] |
CTD |
PMID:26474287 PMID:31715269 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycbp2 |
MYC binding protein 2 |
decreases expression |
ISO |
celastrol results in decreased expression of MYCBP2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498
|
|
G |
Mynn |
myoneurin |
decreases expression |
ISO |
celastrol results in decreased expression of MYNN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:112,779,654...112,797,188
Ensembl chr 2:112,779,657...112,796,397
|
|
G |
Nbn |
nibrin |
decreases expression |
ISO |
celastrol results in decreased expression of NBN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases activity multiple interactions |
EXP ISO |
celastrol results in increased expression of NFE2L2 protein celastrol results in increased expression of NFE2L2 mRNA celastrol results in increased activity of NFE2L2 protein celastrol inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of and results in decreased activity of NFE2L2 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:26768587 PMID:29643811 PMID:30588110 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased expression of NFKBIA protein modified form] |
CTD |
PMID:30588110 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkd1 |
NKD inhibitor of WNT signaling pathway 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
decreases expression |
ISO |
celastrol results in decreased expression of NKX3-1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]] |
CTD |
PMID:32470352 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:31901889 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notum |
NOTUM, palmitoleoyl-protein carboxylesterase |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr10:105,933,245...105,940,327
Ensembl chr10:105,933,249...105,940,315
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Bleomycin results in decreased activity of NQO1 protein]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NQO1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of NQO1 protein] |
CTD |
PMID:26768587 PMID:30588110 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
ISO |
celastrol results in decreased expression of NREP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
multiple interactions increases expression |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of OGDH mRNA] celastrol results in increased expression of OGDH mRNA |
CTD |
PMID:35679966 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
decreases expression |
ISO |
celastrol results in decreased expression of OPRK1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oser1 |
oxidative stress responsive serine-rich 1 |
increases expression |
ISO |
celastrol results in increased expression of OSER1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein]; TNFRSF10B protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein] celastrol results in increased cleavage of PARP1 protein |
CTD |
PMID:20605676 PMID:31715269 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
celastrol promotes the reaction [[coomassie Brilliant Blue co-treated with Acetaminophen] results in increased expression of PCNA protein] |
CTD |
PMID:28435131 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pde9a |
phosphodiesterase 9A |
decreases expression |
ISO |
celastrol results in decreased expression of PDE9A mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
decreases phosphorylation multiple interactions |
ISO |
celastrol results in decreased phosphorylation of PDHA1 protein celastrol inhibits the reaction [Dietary Fats results in increased phosphorylation of PDHA1 protein] |
CTD |
PMID:35679966 |
|
NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pdhb |
pyruvate dehydrogenase E1 subunit beta |
multiple interactions increases expression |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDHB mRNA] celastrol results in increased expression of PDHB mRNA |
CTD |
PMID:35679966 |
|
NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression multiple interactions |
ISO |
celastrol results in decreased expression of PDK4 mRNA; celastrol results in decreased expression of PDK4 protein celastrol inhibits the reaction [Dietary Fats results in increased expression of PDK4 mRNA]; celastrol inhibits the reaction [Dietary Fats results in increased expression of PDK4 protein] |
CTD |
PMID:35679966 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp1 |
pyruvate dehydrogenase phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDP1 mRNA]; celastrol inhibits the reaction [Dietary Fats results in decreased expression of PDP1 protein] celastrol results in increased expression of PDP1 mRNA; celastrol results in increased expression of PDP1 protein |
CTD |
PMID:35679966 |
|
NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PFKM mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of PGAM1 mRNA celastrol inhibits the reaction [Dietary Fats results in decreased expression of PGAM1 mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [Dietary Fats results in decreased expression of PGK1 mRNA] |
CTD |
PMID:35679966 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases expression |
ISO |
celastrol results in decreased expression of PIK3CD mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases expression |
ISO |
celastrol results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions increases expression |
ISO |
[celastrol co-treated with Dietary Fats] results in increased expression of PKM mRNA celastrol results in increased expression of PKM mRNA |
CTD |
PMID:35679966 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plin1 |
perilipin 1 |
affects expression |
ISO |
celastrol affects the expression of PLIN1 mRNA |
CTD |
PMID:27085773 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression |
ISO |
celastrol affects the expression of PPARG mRNA; celastrol affects the expression of PPARG protein |
CTD |
PMID:27085773 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppif |
peptidylprolyl isomerase F |
decreases expression |
ISO |
celastrol results in decreased expression of PPIF mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
celastrol inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:24111524 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
celastrol results in increased expression of PTGS1 mRNA |
CTD |
PMID:25477506 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
celastrol results in decreased expression of PTGS2 mRNA; celastrol results in decreased expression of PTGS2 protein |
CTD |
PMID:31715269 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pura |
purine rich element binding protein A |
decreases expression |
ISO |
celastrol results in decreased expression of PURA mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:27,885,071...27,905,509
Ensembl chr18:27,884,556...27,905,513
|
|
G |
Rac3 |
Rac family small GTPase 3 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
celastrol inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] celastrol inhibits the reaction [Plant Preparations results in increased expression of RELA protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased activity of RELA protein] |
CTD |
PMID:16769766 PMID:29643811 PMID:30588110 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; PTEN protein promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:24111524 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
celastrol results in decreased expression of RRM2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of SDHB mRNA celastrol inhibits the reaction [Dietary Fats results in decreased expression of SDHB mRNA]; celastrol inhibits the reaction [Dietary Fats results in decreased expression of SDHB protein] |
CTD |
PMID:35679966 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
celastrol inhibits the reaction [IL1B protein results in increased expression of SELE protein]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:16769766 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serp1 |
stress-associated endoplasmic reticulum protein 1 |
increases expression |
ISO |
celastrol results in increased expression of SERP1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
ISO |
celastrol results in decreased expression of SESN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
celastrol results in increased expression of SLC3A2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases response to substance increases expression |
ISO |
SLC7A11 protein results in decreased susceptibility to celastrol celastrol results in increased expression of SLC7A11 mRNA |
CTD |
PMID:17010675 PMID:20007406 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sltm |
SAFB-like, transcription modulator |
decreases expression |
ISO |
celastrol results in decreased expression of SLTM mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:71,215,995...71,261,821
Ensembl chr 8:71,216,612...71,261,825
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
celastrol inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:29789558 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Bleomycin results in decreased activity of SOD2 protein] |
CTD |
PMID:26768587 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
decreases expression |
ISO |
celastrol results in decreased expression of SOX4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
EXP |
celastrol results in decreased expression of SQSTM1 protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol results in decreased expression of SQSTM1 protein] |
CTD |
PMID:32470352 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
increases expression |
ISO |
celastrol results in increased expression of STIP1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Taok3 |
TAO kinase 3 |
decreases expression |
ISO |
celastrol results in decreased expression of TAOK3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:39,312,354...39,473,656
Ensembl chr12:39,314,027...39,461,244
|
|
G |
Tcf7 |
transcription factor 7 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
celastrol inhibits the reaction [TGFB1 protein results in decreased expression of CNR2 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; celastrol inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] celastrol inhibits the reaction [Doxorubicin results in increased expression of TGFB1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:29789558 PMID:30588110 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 mRNA]; celastrol inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] |
CTD |
PMID:30588110 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
celastrol inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of SELE protein]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] celastrol inhibits the reaction [Bleomycin results in increased expression of TNF protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]] celastrol results in increased expression of TNF mRNA celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; celastrol inhibits the reaction [Plant Preparations results in increased expression of TNF protein]; celastrol promotes the reaction [Dextran Sulfate results in increased expression of TNF protein] |
CTD |
PMID:16769766 PMID:24384223 PMID:25477506 PMID:26768587 PMID:29643811 PMID:30588110 PMID:31715269 PMID:31901889 PMID:32470352 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of TNFRSF10A mRNA celastrol results in increased expression of and results in increased localization of TNFRSF10A protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein] |
CTD |
PMID:20605676 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases expression increases response to substance |
ISO |
[TNFSF10 protein co-treated with celastrol] results in increased cleavage of CASP3 protein; [TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein; TNFRSF10A protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein]; TNFRSF10B protein promotes the reaction [[TNFSF10 protein co-treated with celastrol] results in increased cleavage of PARP1 protein] celastrol results in increased expression of TNFSF10 mRNA celastrol results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:20605676 PMID:25477506 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased secretion of TNNI3 protein] |
CTD |
PMID:30588110 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
celastrol inhibits the reaction [Doxorubicin results in increased secretion of TNNT2 protein] |
CTD |
PMID:30588110 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
celastrol results in increased expression of TP53 protein Uridine inhibits the reaction [celastrol results in increased expression of TP53 protein] |
CTD |
PMID:27374097 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
celastrol results in decreased expression of TXNIP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
celastrol results in increased expression of TXNRD1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
increases expression |
ISO |
celastrol results in increased expression of UBE2B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Uck1 |
uridine-cytidine kinase 1 |
increases expression |
ISO |
celastrol results in increased expression of UCK1 mRNA |
CTD |
PMID:27374097 |
|
NCBI chr 3:15,538,580...15,544,465
Ensembl chr 3:15,538,591...15,544,465
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
increases expression |
ISO |
celastrol results in increased expression of UGDH mRNA |
CTD |
PMID:17010675 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [IFNG protein results in increased expression of VCAM1 protein]; celastrol inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; celastrol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:16769766 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Wdr77 |
WD repeat domain 77 |
decreases expression |
ISO |
celastrol results in decreased expression of WDR77 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:193,435,465...193,445,534
Ensembl chr 2:193,435,468...193,445,520
|
|
G |
Wif1 |
Wnt inhibitory factor 1 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360
|
|
G |
Wnt10a |
Wnt family member 10A |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
|
|
G |
Wnt3 |
Wnt family member 3 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:76,329,882...76,343,523
|
|
G |
Wnt7b |
Wnt family member 7B |
multiple interactions |
ISO |
celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 7:116,634,817...116,679,459
Ensembl chr 7:116,634,814...116,679,581
|
|
G |
Zbtb43 |
zinc finger and BTB domain containing 43 |
decreases expression |
ISO |
celastrol results in decreased expression of ZBTB43 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:16,744,535...16,763,854
Ensembl chr 3:16,744,535...16,763,909
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
decreases expression |
ISO |
celastrol results in decreased expression of ZC3H12A mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351
|
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:12804013 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CRYZ protein] |
CTD |
PMID:12804013 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of G6PD protein] |
CTD |
PMID:12804013 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein] |
CTD |
PMID:12804013 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein] |
CTD |
PMID:12804013 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of XDH protein] |
CTD |
PMID:12804013 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
ISO |
cycloastragenol results in increased expression of AQP9 mRNA; cycloastragenol results in increased expression of AQP9 protein |
CTD |
PMID:37918281 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Arhgap17 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:177,807,579...177,897,027
Ensembl chr 1:177,807,583...177,896,854
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Bax protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
cycloastragenol results in increased expression of CCND1 protein |
CTD |
PMID:37918281 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Dsc2 |
desmocollin 2 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Dsc2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Gsk3b protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Ifng protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Ikbkg protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il10 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il17 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il1b protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Il4 protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il6 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Mt-co2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
ISO |
cycloastragenol results in increased expression of PCNA protein |
CTD |
PMID:37918281 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Plcg1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Rhoa protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rit2 |
Ras-like without CAAX 2 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Rit2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:22,565,403...22,921,648
Ensembl chr18:22,565,404...22,921,648
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Tnf protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Zeb1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Ahsa1 |
activator of Hsp90 ATPase activity 1 |
increases expression |
ISO |
gedunin results in increased expression of AHSA1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
gedunin results in increased expression of AKR1C1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
gedunin results in increased expression of AKR1C2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
gedunin results in decreased expression of AR protein |
CTD |
PMID:17010675 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
gedunin results in decreased expression of ARID5B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
gedunin results in increased expression of ATF3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
ISO |
gedunin results in increased expression of BAG3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
gedunin results in decreased expression of BIRC5 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
gedunin results in decreased expression of BTG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Cacybp |
calcyclin binding protein |
increases expression |
ISO |
gedunin results in increased expression of CACYBP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
gedunin results in increased activity of CASP3 protein |
CTD |
PMID:21381696 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
gedunin results in increased activity of CASP8 protein |
CTD |
PMID:21381696 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
gedunin results in increased activity of CASP9 protein |
CTD |
PMID:21381696 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
gedunin results in increased expression of CBR3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cdc7 |
cell division cycle 7 |
decreases expression |
ISO |
gedunin results in decreased expression of CDC7 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr14:2,804,660...2,824,796
Ensembl chr14:2,804,661...2,824,778
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
gedunin results in decreased expression of CDK2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
gedunin results in increased expression of CHORDC1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
ISO |
gedunin results in decreased expression of CITED2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression |
ISO |
gedunin results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
gedunin results in increased expression of DDIT3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
gedunin results in increased expression of DDIT4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
increases expression |
ISO |
gedunin results in increased expression of DNAJA1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
gedunin results in increased expression of DNAJB4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Efnb2 |
ephrin B2 |
decreases expression |
ISO |
gedunin results in decreased expression of EFNB2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
gedunin results in decreased expression of EGFR protein |
CTD |
PMID:17010675 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ficd |
FIC domain protein adenylyltransferase |
increases expression |
ISO |
gedunin results in increased expression of FICD mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:42,889,195...42,894,090
Ensembl chr12:42,889,194...42,894,070
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression |
ISO |
gedunin results in decreased expression of FLT3 protein |
CTD |
PMID:17010675 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Gatd3a |
glutamine amidotransferase class 1 domain containing 3A |
decreases expression |
ISO |
gedunin results in decreased expression of GATD3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
gedunin results in increased expression of GCLM mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
gedunin results in increased expression of GDF15 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
increases expression |
ISO |
gedunin results in increased expression of GTPBP2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
decreases expression |
ISO |
gedunin results in decreased expression of HILPDA mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
gedunin results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
gedunin results in increased expression of HMOX1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases activity |
ISO |
gedunin results in decreased activity of HSP90AA1 protein |
CTD |
PMID:17010675 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa13 |
heat shock protein family A (Hsp70) member 13 |
increases expression |
ISO |
gedunin results in increased expression of HSPA13 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
ISO |
gedunin results in increased expression of HSPA1A mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
gedunin results in increased expression of HSPA1B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
gedunin results in increased expression of HSPA5 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
gedunin results in increased expression of HSPH1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
ISO |
gedunin results in decreased expression of IL1RN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
gedunin results in increased expression of INSIG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
gedunin results in decreased expression of JAG1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
ISO |
gedunin results in decreased expression of KCNN2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
gedunin results in increased expression of LDLR mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
gedunin results in increased expression of LPIN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ltn1 |
listerin E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
gedunin results in decreased expression of LTN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr11:26,603,903...26,660,871
Ensembl chr11:26,603,903...26,660,886
|
|
G |
Mafb |
MAF bZIP transcription factor B |
decreases expression |
ISO |
gedunin results in decreased expression of MAFB mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
decreases expression |
ISO |
gedunin results in decreased expression of MDH2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
gedunin results in increased expression of ME1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mnt |
MAX network transcriptional repressor |
increases expression |
ISO |
gedunin results in increased expression of MNT mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:59,699,208...59,714,848
Ensembl chr10:59,699,585...59,714,835
|
|
G |
Mrpl18 |
mitochondrial ribosomal protein L18 |
increases expression |
ISO |
gedunin results in increased expression of MRPL18 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:47,837,169...47,841,987
Ensembl chr 1:47,836,561...47,841,987
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
gedunin results in decreased expression of MSH6 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
gedunin results in increased expression of MSMO1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mycbp2 |
MYC binding protein 2 |
decreases expression |
ISO |
gedunin results in decreased expression of MYCBP2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498
|
|
G |
Mynn |
myoneurin |
decreases expression |
ISO |
gedunin results in decreased expression of MYNN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:112,779,654...112,797,188
Ensembl chr 2:112,779,657...112,796,397
|
|
G |
Nbn |
nibrin |
decreases expression |
ISO |
gedunin results in decreased expression of NBN mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
decreases expression |
ISO |
gedunin results in decreased expression of NKX3-1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
ISO |
gedunin results in decreased expression of NREP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
decreases expression |
ISO |
gedunin results in decreased expression of OPRK1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oser1 |
oxidative stress responsive serine-rich 1 |
increases expression |
ISO |
gedunin results in increased expression of OSER1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149
|
|
G |
Pde9a |
phosphodiesterase 9A |
decreases expression |
ISO |
gedunin results in decreased expression of PDE9A mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases expression |
ISO |
gedunin results in decreased expression of PIK3CD mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases expression |
ISO |
gedunin results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[gedunin co-treated with Glucose] binds to PPARA protein; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:18812576 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppif |
peptidylprolyl isomerase F |
decreases expression |
ISO |
gedunin results in decreased expression of PPIF mRNA |
CTD |
PMID:17010675 |
|
NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913
|
|
G |
Pura |
purine rich element binding protein A |
decreases expression |
ISO |
gedunin results in decreased expression of PURA mRNA |
CTD |
PMID:17010675 |
|
NCBI chr18:27,885,071...27,905,509
Ensembl chr18:27,884,556...27,905,513
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
gedunin results in decreased expression of RRM2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Serp1 |
stress-associated endoplasmic reticulum protein 1 |
increases expression |
ISO |
gedunin results in increased expression of SERP1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
ISO |
gedunin results in decreased expression of SESN1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
gedunin results in increased expression of SLC3A2 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
gedunin results in increased expression of SLC7A11 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sltm |
SAFB-like, transcription modulator |
decreases expression |
ISO |
gedunin results in decreased expression of SLTM mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 8:71,215,995...71,261,821
Ensembl chr 8:71,216,612...71,261,825
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
decreases expression |
ISO |
gedunin results in decreased expression of SOX4 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
increases expression |
ISO |
gedunin results in increased expression of STIP1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Taok3 |
TAO kinase 3 |
decreases expression |
ISO |
gedunin results in decreased expression of TAOK3 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr12:39,312,354...39,473,656
Ensembl chr12:39,314,027...39,461,244
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
gedunin results in decreased expression of TXNIP mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
gedunin results in increased expression of TXNRD1 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
increases expression |
ISO |
gedunin results in increased expression of UBE2B mRNA |
CTD |
PMID:17010675 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
increases expression |
ISO |
gedunin results in increased expression of UGDH mRNA |
CTD |
PMID:17010675 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Wdr77 |
WD repeat domain 77 |
decreases expression |
ISO |
gedunin results in decreased expression of WDR77 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 2:193,435,465...193,445,534
Ensembl chr 2:193,435,468...193,445,520
|
|
G |
Zbtb43 |
zinc finger and BTB domain containing 43 |
decreases expression |
ISO |
gedunin results in decreased expression of ZBTB43 mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 3:16,744,535...16,763,854
Ensembl chr 3:16,744,535...16,763,909
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
decreases expression |
ISO |
gedunin results in decreased expression of ZC3H12A mRNA |
CTD |
PMID:17010675 |
|
NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein] |
CTD |
PMID:16904803 PMID:18204840 PMID:24380838 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions increases activity |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] Glycyrrhetinic Acid results in increased activity of ABCC1 protein [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon |
CTD |
PMID:18204840 PMID:28549656 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects activity decreases activity |
ISO |
18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein |
CTD |
PMID:11165023 PMID:12604236 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Glycyrrhetinic Acid |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3] |
CTD |
PMID:35699857 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein] |
CTD |
PMID:31325423 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] |
CTD |
PMID:10460758 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein |
CTD |
PMID:21800547 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA] |
CTD |
PMID:29444456 PMID:35699857 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein] |
CTD |
PMID:28414158 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein] |
CTD |
PMID:28414158 PMID:28549656 PMID:36807597 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:28414158 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
Glycyrrhetinic Acid results in decreased expression of HRAS protein |
CTD |
PMID:19958823 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein |
CTD |
PMID:24135201 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity multiple interactions |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein] |
CTD |
PMID:24135201 PMID:31927052 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein] |
CTD |
PMID:10460758 PMID:23373965 PMID:28414158 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] |
CTD |
PMID:21644799 PMID:23373965 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
multiple interactions increases expression |
ISO |
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:28213090 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein] |
CTD |
PMID:29444456 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23373965 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23373965 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein] |
CTD |
PMID:36807597 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:23341968 PMID:28414158 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein] |
CTD |
PMID:24613819 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein] |
CTD |
PMID:23373965 PMID:24613819 PMID:28213090 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] |
CTD |
PMID:21644799 PMID:23373965 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver] |
RGD |
PMID:30061734 |
RGD:15092071 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein |
CTD |
PMID:21644799 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein |
CTD |
PMID:21644799 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein] |
CTD |
PMID:28414158 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:21644799 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:23373965 PMID:24613819 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of REN protein |
CTD |
PMID:20460744 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein] |
CTD |
PMID:31325423 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein] |
CTD |
PMID:31325423 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rock2 |
Rho-associated coiled-coil containing protein kinase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form] |
CTD |
PMID:29444456 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glycyrrhizic Acid results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of ACHE protein] |
CTD |
PMID:31150628 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of ACTA2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:32525084 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Glycyrrhizic Acid |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Gentamicins results in decreased expression of AQP2 protein] |
CTD |
PMID:12969435 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased expression of AQP5 protein] |
CTD |
PMID:29452068 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Ar |
androgen receptor |
multiple interactions affects localization |
ISO |
Glycyrrhizic Acid binds to and results in increased activity of AR protein Glycyrrhizic Acid affects the localization of AR protein |
CTD |
PMID:28478275 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of BAD mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of BAX mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of BCL2 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of BDNF protein] |
CTD |
PMID:31150628 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP2 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP ISO |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP3 protein]; Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of CASP3 protein] Glycyrrhizic Acid results in increased activity of CASP3 protein |
CTD |
PMID:22051199 PMID:31150628 PMID:35844403 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP6 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
EXP ISO |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP8 protein] Glycyrrhizic Acid results in increased activity of CASP8 protein |
CTD |
PMID:22051199 PMID:35844403 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
EXP ISO |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP9 protein] Glycyrrhizic Acid results in increased activity of CASP9 protein |
CTD |
PMID:22051199 PMID:35844403 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA] |
CTD |
PMID:27585667 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of CCND1 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of CDH1 protein |
CTD |
PMID:33522686 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of CDK4 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of CDKN1A mRNA |
CTD |
PMID:35844403 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:29452068 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
Glycyrrhizic Acid results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A4 protein |
CTD |
PMID:22982774 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Glycyrrhizic Acid results in decreased expression of CYP7A1 mRNA Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:22982774 PMID:28549656 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in decreased activity of EPHX2 protein] |
CTD |
PMID:22051199 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Glycyrrhizic Acid inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with BCG Vaccine] results in increased activity of GPT protein] Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein] |
CTD |
PMID:19196740 PMID:28549656 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of HES1 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases secretion multiple interactions decreases activity |
ISO EXP |
Glycyrrhizic Acid results in decreased secretion of HMGB1 protein Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] Glycyrrhizic Acid results in decreased activity of HMGB1 protein |
CTD |
PMID:27585667 PMID:27689324 PMID:27783111 PMID:32525084 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein] |
CTD |
PMID:17917259 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression |
EXP |
Glycyrrhizic Acid results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Ifng |
interferon gamma |
affects expression |
ISO |
Glycyrrhizic Acid affects the expression of IFNG mRNA |
CTD |
PMID:16945185 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12A mRNA |
CTD |
PMID:11412311 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B mRNA; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B protein |
CTD |
PMID:11412311 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein] |
CTD |
PMID:21644799 PMID:26524701 PMID:29452068 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPB mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPD mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34302803 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of JAG1 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32525084 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34302803 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34302803 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Picryl Chloride results in increased secretion of MMP2 protein] |
CTD |
PMID:16945185 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of MTOR protein] |
CTD |
PMID:32525084 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of MUC5AC protein] |
CTD |
PMID:29452068 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:11412311 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29452068 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:17917259 PMID:21644799 PMID:23373965 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of NOTCH1 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of NR0B2 mRNA |
CTD |
PMID:22982774 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Glycyrrhizic Acid results in increased activity of NR1I2 protein NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:22982774 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of PIK3CD protein |
CTD |
PMID:21644799 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of PIK3CG protein |
CTD |
PMID:21644799 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:17917259 PMID:21644799 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rad21 |
RAD21 cohesin complex component |
decreases binding |
ISO |
Glycyrrhizinic acid decreases binding of RAD21 protein to SMC3 protein in lymphoma cells |
RGD |
PMID:21880767 |
RGD:243065267 |
NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of RELA protein] Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene affects the localization of RELA protein]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased phosphorylation of RELA protein] |
CTD |
PMID:11412311 PMID:22051199 PMID:26524701 PMID:29452068 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of REN protein |
CTD |
PMID:20460744 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SCD1 mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SIRT1 protein] |
CTD |
PMID:25162824 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of SLC2A4 mRNA] |
CTD |
PMID:34302803 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Smad4 |
SMAD family member 4 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of SMAD4 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of SMAD7 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SOD2 protein] |
CTD |
PMID:25162824 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid affects the reaction [Doxorubicin results in increased expression of SQSTM1 protein] |
CTD |
PMID:32525084 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in increased expression of TGFB1 protein] |
CTD |
PMID:25162824 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of TGFBR1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
decreases expression |
ISO |
Glycyrrhizic Acid results in decreased expression of TGFBR2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:27689324 PMID:27783111 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tjp2 |
tight junction protein 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP2 protein] |
CTD |
PMID:27689324 PMID:27783111 |
|
NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein] |
CTD |
PMID:17917259 PMID:21644799 PMID:26524701 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of TP53 mRNA |
CTD |
PMID:35844403 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
decreases expression |
ISO |
lupeol results in decreased expression of ABCG2 protein |
CTD |
PMID:20979057 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 results in increased expression of AKT1 protein] |
CTD |
PMID:35446470 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 results in increased activity of ALOX5 protein] |
CTD |
PMID:35446470 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA] lupeol inhibits the reaction [COL2A1 results in decreased expression of BAX protein] lupeol results in increased expression of BAX mRNA; lupeol results in increased expression of BAX protein |
CTD |
PMID:27235710 PMID:30506710 PMID:31112703 PMID:35446470 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] lupeol inhibits the reaction [COL2A1 results in increased expression of BCL2 protein] lupeol results in decreased expression of BCL2 mRNA; lupeol results in decreased expression of BCL2 protein |
CTD |
PMID:27235710 PMID:30506710 PMID:31112703 PMID:35446470 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
lupeol results in increased expression of CASP3 mRNA; lupeol results in increased expression of CASP3 protein lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP3 protein] |
CTD |
PMID:30506710 PMID:35446470 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
lupeol results in increased expression of CASP8 mRNA; lupeol results in increased expression of CASP8 protein |
CTD |
PMID:30506710 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions |
ISO EXP |
lupeol results in increased expression of CASP9 mRNA; lupeol results in increased expression of CASP9 protein lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP9 protein] |
CTD |
PMID:30506710 PMID:35446470 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol inhibits the reaction [Sodium Selenite results in decreased activity of CAT protein] lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:16933029 PMID:26697995 PMID:27235710 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
lupeol results in decreased expression of CCND1 mRNA |
CTD |
PMID:20732907 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
lupeol results in increased expression of CDH1 mRNA; lupeol results in increased expression of CDH1 protein |
CTD |
PMID:31112703 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 protein results in increased secretion of Dinoprostone]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of IL6 protein]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of TNF protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of BAX protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP3 protein]; lupeol inhibits the reaction [COL2A1 results in decreased expression of CASP9 protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of ALOX5 protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of MPO protein]; lupeol inhibits the reaction [COL2A1 results in increased activity of PTGS2 protein]; lupeol inhibits the reaction [COL2A1 results in increased expression of AKT1 protein]; lupeol inhibits the reaction [COL2A1 results in increased expression of BCL2 protein]; lupeol inhibits the reaction [COL2A1 results in increased secretion of CP protein]; lupeol inhibits the reaction [COL2A1 results in increased secretion of CRP protein] |
CTD |
PMID:35446470 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 results in increased secretion of CP protein] |
CTD |
PMID:35446470 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 results in increased secretion of CRP protein] |
CTD |
PMID:35446470 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
lupeol inhibits the reaction [Benzoyl Peroxide affects the activity of CRYZ protein] |
CTD |
PMID:15248479 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
ISO |
lupeol results in decreased expression of CTNNB1 protein lupeol results in decreased localization of and results in decreased activity of CTNNB1 protein |
CTD |
PMID:20732907 PMID:20979057 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
affects binding |
EXP |
lupeol binds to GSK3B protein |
CTD |
PMID:18222664 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
lupeol inhibits the reaction [Sodium Selenite results in decreased activity of GSR protein] |
CTD |
PMID:26697995 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
lupeol results in decreased expression of IL10 mRNA |
CTD |
PMID:31112703 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
lupeol results in decreased expression of IL1B mRNA |
CTD |
PMID:31112703 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO EXP |
lupeol results in decreased expression of IL6 mRNA lupeol inhibits the reaction [COL2A1 protein results in increased secretion of IL6 protein] |
CTD |
PMID:31112703 PMID:35446470 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
lupeol results in decreased expression of MKI67 mRNA |
CTD |
PMID:20732907 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO EXP |
[lupeol binds to stearic acid] inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of MPO protein] lupeol inhibits the reaction [COL2A1 results in increased activity of MPO protein] |
CTD |
PMID:32006539 PMID:35446470 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
lupeol results in decreased expression of MYC mRNA |
CTD |
PMID:20732907 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
lupeol results in decreased expression of NANOG protein |
CTD |
PMID:20979057 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nes |
nestin |
decreases expression |
ISO |
lupeol results in decreased expression of NES protein |
CTD |
PMID:20979057 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
lupeol results in decreased expression of PCNA mRNA |
CTD |
PMID:20732907 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
lupeol results in decreased expression of POU5F1 protein |
CTD |
PMID:20979057 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
ISO |
lupeol results in decreased expression of PROM1 protein |
CTD |
PMID:20979057 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression increases response to substance |
ISO |
lupeol results in increased expression of PTEN protein PTEN protein results in increased susceptibility to lupeol |
CTD |
PMID:20979057 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
lupeol inhibits the reaction [COL2A1 results in increased activity of PTGS2 protein] |
CTD |
PMID:35446470 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb affects the localization of RELA protein] |
CTD |
PMID:27235710 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
lupeol results in decreased expression of SOX2 protein |
CTD |
PMID:20979057 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
lupeol results in decreased expression of TNF mRNA lupeol inhibits the reaction [COL2A1 protein results in increased secretion of TNF protein] |
CTD |
PMID:31112703 PMID:35446470 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
lupeol inhibits the reaction [Benzoyl Peroxide affects the activity of XDH protein] |
CTD |
PMID:15248479 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions |
ISO |
lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA] madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:37087747 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA] |
CTD |
PMID:37087747 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:37087747 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP2C19 protein |
CTD |
PMID:21349323 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP3A4 protein |
CTD |
PMID:21349323 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of HAVCR1 mRNA] |
CTD |
PMID:37087747 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of IL1B mRNA] |
CTD |
PMID:37087747 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of IL6 mRNA] |
CTD |
PMID:37087747 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 mRNA]; madecassoside inhibits the reaction [Cisplatin results in increased expression of LCN2 protein] |
CTD |
PMID:37087747 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:37087747 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:37087747 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
madecassoside inhibits the reaction [Cisplatin results in increased expression of TNF mRNA] |
CTD |
PMID:37087747 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:26513295 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of JUN protein]; maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein] |
CTD |
PMID:26513295 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Pdcd4 |
programmed cell death 4 |
multiple interactions |
ISO |
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PDCD4 protein] |
CTD |
PMID:26513295 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] |
CTD |
PMID:26513295 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of SRC protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of SRC protein] |
CTD |
PMID:26513295 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of STAT3 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:26513295 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
maslinic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased phosphorylation of STK11 protein]; maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased phosphorylation of STK11 protein] |
CTD |
PMID:26513295 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[maslinic acid analog co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of ULK1 protein |
CTD |
PMID:26513295 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
maslinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of ABCB11 mRNA; Oleanolic Acid results in decreased expression of ABCB11 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA] |
CTD |
PMID:23948738 PMID:36846903 PMID:37028458 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of ABCC2 mRNA; Oleanolic Acid results in decreased expression of ABCC2 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:36846903 PMID:37028458 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Oleanolic Acid results in increased expression of ABCG2 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
Oleanolic Acid analog inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17922224 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
EXP |
Oleanolic Acid inhibits the reaction [Ethanol results in increased expression of and results in increased activity of ADH1 protein] |
CTD |
PMID:25111957 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of AGER protein] |
CTD |
PMID:22386814 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in decreased susceptibility to Doxorubicin]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal]; Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-oxo-2-nonenal] |
CTD |
PMID:25686905 PMID:27417252 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP ISO |
[Fructose co-treated with Oleanolic Acid] results in increased expression of AKT1 mRNA Oleanolic Acid results in decreased phosphorylation of AKT1 protein Oleanolic Acid analog results in increased phosphorylation of AKT1 protein |
CTD |
PMID:24704288 PMID:26612655 PMID:35690101 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atg5 |
autophagy related 5 |
increases expression multiple interactions |
ISO |
Oleanolic Acid analog results in increased expression of ATG5 protein; Oleanolic Acid results in increased expression of ATG5 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of ATG5 protein] |
CTD |
PMID:26612655 PMID:31306688 PMID:35690101 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Oleanolic Acid analog results in increased expression of BAX protein; Oleanolic Acid results in increased expression of BAX protein [Oleanolic Acid analog binds to Succinic Acid] which results in increased expression of BAX mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in increased expression of BAX protein; [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BAX mRNA; Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]] |
CTD |
PMID:26612655 PMID:31401087 PMID:33465424 PMID:34364837 PMID:37345903 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Oleanolic Acid analog results in decreased expression of BCL2 protein; Oleanolic Acid results in decreased expression of BCL2 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BCL2 mRNA; Cisplatin promotes the reaction [Oleanolic Acid results in decreased expression of BCL2 protein]; Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]; Oleanolic Acid promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]] |
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 PMID:34364837 PMID:37345903 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of BCL2L1 mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of BCL2L1 protein |
CTD |
PMID:31401087 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
affects expression increases expression |
ISO |
Oleanolic Acid analog affects the expression of BECN1 protein Oleanolic Acid results in increased expression of BECN1 protein |
CTD |
PMID:26612655 PMID:35690101 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of BIRC5 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BIRC5 mRNA |
CTD |
PMID:22678527 PMID:37345903 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage decreases expression increases expression |
ISO |
Oleanolic Acid results in increased activity of CASP3 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of CASP3 mRNA; Ascorbic Acid inhibits the reaction [Oleanolic Acid results in increased cleavage of CASP3 protein]; Cisplatin inhibits the reaction [Oleanolic Acid results in increased cleavage of CASP3 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Oleanolic Acid inhibits the reaction [ochratoxin A results in increased cleavage of CASP3 protein] Oleanolic Acid analog results in decreased expression of CASP3 protein Oleanolic Acid results in increased expression of CASP3 protein |
CTD |
PMID:20005942 PMID:20726234 PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 PMID:35690101 PMID:37345903 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
Oleanolic Acid results in increased activity of CASP8 protein [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of CASP8 mRNA |
CTD |
PMID:20005942 PMID:37345903 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression multiple interactions increases cleavage |
ISO |
Oleanolic Acid analog results in decreased expression of CASP9 protein Oleanolic Acid inhibits the reaction [ochratoxin A results in increased cleavage of CASP9 protein] Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] Oleanolic Acid results in increased cleavage of CASP9 protein |
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:33465424 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases expression multiple interactions |
EXP ISO |
Oleanolic Acid results in increased expression of CAT mRNA Oleanolic Acid inhibits the reaction [Paraquat results in increased activity of CAT protein] Oleanolic Acid inhibits the reaction [Ethanol results in increased activity of CAT protein] Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CAT protein] |
CTD |
PMID:18706400 PMID:20100471 PMID:21801858 PMID:25111957 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression |
ISO EXP |
Oleanolic Acid results in increased expression of CCND1 mRNA Oleanolic Acid results in decreased expression of CCND1 protein |
CTD |
PMID:18706400 PMID:20726234 PMID:35690101 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
ISO |
oleanolic acid decreases expression of CCNG1 protein in human lung carcinoma xenografts in mouse |
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:32894642 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions decreases expression |
EXP ISO |
Oleanolic Acid results in increased expression of CDKN1A mRNA Oleanolic Acid results in increased expression of CDKN1A protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of CDKN1A protein] Oleanolic Acid results in decreased expression of CDKN1A protein |
CTD |
PMID:18706400 PMID:22678527 PMID:31306688 PMID:35690101 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein] |
CTD |
PMID:32894642 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Oleanolic Acid analog results in decreased expression of COL1A1 mRNA |
CTD |
PMID:17922224 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Oleanolic Acid results in increased expression of CXCL2 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of CXCL2 mRNA]; Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA] |
CTD |
PMID:25280775 PMID:26513295 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of CXCL1 mRNA] |
CTD |
PMID:25280775 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
increases expression |
EXP |
Oleanolic Acid results in increased expression of CXCL5 mRNA |
CTD |
PMID:18706400 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of CYCS protein] |
CTD |
PMID:33465424 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases expression decreases activity |
ISO EXP |
Oleanolic Acid inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] Oleanolic Acid results in decreased expression of CYP1A2 mRNA Oleanolic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:15043991 PMID:18706400 PMID:23948738 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of CYP2B10 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases expression |
ISO EXP |
Oleanolic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] Oleanolic Acid inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] Oleanolic Acid results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:10355542 PMID:18706400 PMID:25111957 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of CYP2F2 mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Oleanolic Acid inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam] Oleanolic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:15043991 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of CYP7A1 mRNA; Oleanolic Acid results in decreased expression of CYP7A1 protein GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:23948738 PMID:37028458 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of CYP8B1 mRNA; Oleanolic Acid results in decreased expression of CYP8B1 protein GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 mRNA] |
CTD |
PMID:23948738 PMID:37028458 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of DDIT3 mRNA] Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]] |
CTD |
PMID:25280775 PMID:33465424 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of DIABLO mRNA |
CTD |
PMID:37345903 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Foxo3 |
forkhead box O3 |
affects localization multiple interactions |
ISO |
Oleanolic Acid affects the localization of FOXO3 protein Oleanolic Acid results in increased expression of and results in increased phosphorylation of FOXO3 protein |
CTD |
PMID:35690101 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of GADD45A mRNA] |
CTD |
PMID:25280775 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
EXP ISO |
Oleanolic Acid results in increased expression of GCLC mRNA Oleanolic Acid results in increased expression of GCLC mRNA; Oleanolic Acid results in increased expression of GCLC protein |
CTD |
PMID:18706400 PMID:19283895 PMID:25280775 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Oleanolic Acid results in increased expression of GCLM mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of GHRL protein |
CTD |
PMID:20188082 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; 4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate) inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols; [Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein |
CTD |
PMID:23022524 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions increases response to substance |
ISO |
[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Calcium; Oleanolic Acid binds to and results in increased activity of GPBAR1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; 4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate) inhibits the reaction [[[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols]; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased hydrolysis of Phosphatidylinositols; [Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein; Oleanolic Acid binds to and results in increased activity of GPBAR1 protein GPBAR1 protein results in increased susceptibility to Oleanolic Acid |
CTD |
PMID:23022524 PMID:23041323 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression increases activity |
ISO |
dorsomorphin inhibits the reaction [Oleanolic Acid results in increased expression of GPT protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in increased activity of GPT protein]; Oleanolic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in increased activity of GPT protein] |
CTD |
PMID:10355542 PMID:15720792 PMID:36846903 PMID:37028458 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Oleanolic Acid results in increased expression of GPX1 mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of GSR protein] |
CTD |
PMID:25111957 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of HDAC1 protein |
CTD |
PMID:20726234 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions decreases response to substance decreases expression |
ISO |
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of AGER protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of SELE protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of TNF protein]; Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein]; Oleanolic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of HMGB1 protein] Oleanolic Acid results in decreased susceptibility to HMGB1 protein Oleanolic Acid results in decreased expression of HMGB1 protein |
CTD |
PMID:22386814 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Oleanolic Acid results in increased expression of HMOX1 mRNA Oleanolic Acid results in increased expression of HMOX1 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of HMOX1 mRNA] Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of HMOX1 protein] |
CTD |
PMID:18706400 PMID:19283895 PMID:25111957 PMID:25280775 PMID:35690101 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
multiple interactions |
ISO |
HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCB11 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of ABCC2 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP7A1 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of CYP8B1 protein]]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]] |
CTD |
PMID:37028458 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
Oleanolic Acid results in increased expression of HSPA1B mRNA |
CTD |
PMID:18706400 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]] |
CTD |
PMID:33465424 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of ICAM1 protein Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of ICAM1 protein] |
CTD |
PMID:20005942 PMID:22386814 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of IFNG mRNA] |
CTD |
PMID:21801858 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of RELA protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:32894642 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of IL6 mRNA] |
CTD |
PMID:21801858 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Oleanolic Acid inhibits the reaction [Fructose results in increased expression of INS1 protein] |
CTD |
PMID:24704288 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Glucose] results in increased secretion of INS protein |
CTD |
PMID:23022524 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
[Fructose co-treated with Oleanolic Acid] results in increased expression of INSR mRNA |
CTD |
PMID:24704288 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
[Fructose co-treated with Oleanolic Acid] results in increased expression of IRS1 mRNA; [Fructose co-treated with Oleanolic Acid] results in increased expression of IRS1 protein; Oleanolic Acid inhibits the reaction [Fructose results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:24704288 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Oleanolic Acid results in increased expression of LEP protein |
CTD |
PMID:20188082 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
ISO |
Cisplatin promotes the reaction [Oleanolic Acid results in increased expression of MAP1LC3B protein]; Oleanolic Acid promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein]; Oleanolic Acid results in increased expression of and results in increased lipidation of MAP1LC3B protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of MAP1LC3B protein] |
CTD |
PMID:31306688 PMID:35690101 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of MAPK1 protein modified form] Oleanolic Acid results in increased phosphorylation of MAPK1 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of MAPK1 protein] Oleanolic Acid analog results in decreased phosphorylation of MAPK1 protein; Oleanolic Acid results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:20100471 PMID:26612655 PMID:31306688 PMID:35690101 PMID:36846903 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases phosphorylation |
ISO |
Oleanolic Acid analog results in decreased phosphorylation of MAPK14 protein |
CTD |
PMID:26612655 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of MAPK3 protein modified form] Oleanolic Acid results in increased phosphorylation of MAPK3 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of MAPK3 protein] Oleanolic Acid analog results in decreased phosphorylation of MAPK3 protein; Oleanolic Acid results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:20100471 PMID:26612655 PMID:31306688 PMID:35690101 PMID:36846903 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases phosphorylation |
ISO |
Oleanolic Acid analog results in decreased phosphorylation of MAPK8 protein |
CTD |
PMID:26612655 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
decreases expression |
ISO |
oleanolic acid decreases expression of MEF2D protein in human lung carcinoma xenografts in mouse |
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of MET protein |
CTD |
PMID:20726234 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of MIF mRNA] |
CTD |
PMID:21801858 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mir122 |
microRNA 122 |
increases expression |
ISO |
oleanolic acid increases expression of MIR122 protein in human lung carcinoma xenografts in mouse |
RGD |
PMID:25472877 |
RGD:151361106 |
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA]; Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased secretion of MMP2 protein]; Oleanolic Acid results in decreased secretion of and results in decreased activity of and affects the expression of MMP2 protein |
CTD |
PMID:25686905 PMID:36191607 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; Oleanolic Acid results in decreased secretion of and results in decreased activity of and affects the expression of MMP9 protein |
CTD |
PMID:36191607 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Oleanolic Acid results in increased expression of MT1A mRNA; Oleanolic Acid results in increased expression of MT1A protein |
CTD |
PMID:17637929 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
EXP ISO |
Oleanolic Acid results in increased expression of MT2 mRNA; Oleanolic Acid results in increased expression of MT2A mRNA; Oleanolic Acid results in increased expression of MT2A protein |
CTD |
PMID:17637929 PMID:18706400 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
Oleanolic Acid analog results in decreased phosphorylation of MTOR protein; Oleanolic Acid results in decreased phosphorylation of MTOR protein |
CTD |
PMID:26612655 PMID:35690101 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
EXP ISO |
Oleanolic Acid results in increased expression of MYC mRNA [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of MYC mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of MYC protein |
CTD |
PMID:18706400 PMID:31401087 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression increases activity affects localization |
ISO EXP |
NFE2L2 protein affects the reaction [Oleanolic Acid results in increased activity of NQO1 protein]; NFE2L2 protein affects the reaction [Oleanolic Acid results in increased expression of NQO1 protein]; Oleanolic Acid promotes the reaction [Phalloidine results in increased expression of NFE2L2 mRNA]; Phalloidine promotes the reaction [Oleanolic Acid results in increased expression of NFE2L2 mRNA] Oleanolic Acid results in increased expression of NFE2L2 mRNA; Oleanolic Acid results in increased expression of NFE2L2 protein Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of NFE2L2 protein]; Oleanolic Acid promotes the reaction [Ethanol affects the localization of NFE2L2 protein] Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of NFE2L2 protein]; Oleanolic Acid promotes the reaction [NFE2L2 protein results in increased expression of SREBF1 mRNA] Oleanolic Acid results in increased activity of NFE2L2 protein Oleanolic Acid affects the localization of NFE2L2 protein |
CTD |
PMID:18706400 PMID:19283895 PMID:20100471 PMID:23948738 PMID:25111957 PMID:25280775 PMID:28796629 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of NFKB1 mRNA |
CTD |
PMID:31401087 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation multiple interactions |
ISO |
Oleanolic Acid analog results in decreased phosphorylation of NFKBIA protein; Oleanolic Acid results in decreased phosphorylation of NFKBIA protein Oleanolic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:26612655 PMID:32894642 PMID:34364837 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
NFE2L2 protein affects the reaction [Oleanolic Acid results in increased activity of NQO1 protein]; NFE2L2 protein affects the reaction [Oleanolic Acid results in increased expression of NQO1 protein]; Phalloidine promotes the reaction [Oleanolic Acid results in increased expression of NQO1 mRNA] Oleanolic Acid results in increased expression of NQO1 mRNA; Oleanolic Acid results in increased expression of NQO1 protein |
CTD |
PMID:18706400 PMID:19283895 PMID:23948738 PMID:25280775 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of NR0B2 mRNA GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR0B2 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR0B2 mRNA] |
CTD |
PMID:37028458 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of NR1H4 mRNA; Oleanolic Acid results in decreased expression of NR1H4 protein dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; dorsomorphin inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; HNF1A protein affects the reaction [SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein]; U 0126 inhibits the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA] |
CTD |
PMID:23948738 PMID:36846903 PMID:37028458 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of NR1I3 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
EXP |
Oleanolic Acid results in increased expression of ORM1 mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Oleanolic Acid analog results in increased cleavage of PARP1 protein; Oleanolic Acid results in increased cleavage of PARP1 protein Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] Ascorbic Acid inhibits the reaction [Oleanolic Acid results in increased cleavage of PARP1 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:22678527 PMID:26612655 PMID:31306688 PMID:34364837 PMID:35690101 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
ISO EXP |
Oleanolic Acid results in increased expression of PCNA mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pik3c2g |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma |
multiple interactions |
EXP |
[Fructose co-treated with Oleanolic Acid] results in increased expression of PIK3C2G mRNA |
CTD |
PMID:24704288 |
|
NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
decreases expression |
ISO |
Oleanolic Acid analog results in decreased expression of PIK3CA protein |
CTD |
PMID:26612655 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pink1 |
PTEN induced kinase 1 |
increases expression |
ISO |
Oleanolic Acid results in increased expression of PINK1 protein |
CTD |
PMID:35690101 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions decreases secretion |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of PLAU protein Oleanolic Acid results in decreased secretion of PLAU protein |
CTD |
PMID:36191607 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid] results in increased secretion of and results in decreased expression of PLAUR protein; Oleanolic Acid results in increased secretion of and results in decreased expression of PLAUR protein |
CTD |
PMID:36191607 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of PPARA mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppif |
peptidylprolyl isomerase F |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of PPIF protein] |
CTD |
PMID:33465424 |
|
NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PRDX1 protein] |
CTD |
PMID:20100471 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCB11 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of ABCC2 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 mRNA]; PRKAA1 protein affects the reaction [Oleanolic Acid results in decreased expression of NR1H4 protein] |
CTD |
PMID:36846903 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Oleanolic Acid results in increased expression of PTEN protein |
CTD |
PMID:20726234 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Oleanolic Acid results in increased expression of PTGS2 mRNA [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of PTGS2 mRNA; [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of PTGS2 protein Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Oleanolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] |
CTD |
PMID:18706400 PMID:26513295 PMID:31401087 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
ISO |
[Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of RELA mRNA; Oleanolic Acid analog results in decreased expression of and affects the localization of RELA protein; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of RELA protein] Oleanolic Acid analog results in decreased expression of RELA protein |
CTD |
PMID:26362502 PMID:26612655 PMID:31401087 PMID:32894642 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of SELE protein] |
CTD |
PMID:22386814 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
GW 4064 inhibits the reaction [Oleanolic Acid results in decreased expression of SIRT1 protein]; SRT1720 inhibits the reaction [Oleanolic Acid results in decreased expression of SIRT1 protein] Oleanolic Acid results in decreased expression of SIRT1 mRNA; Oleanolic Acid results in decreased expression of SIRT1 protein |
CTD |
PMID:37028458 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of SLC10A1 mRNA; Oleanolic Acid results in decreased expression of SLC10A1 protein |
CTD |
PMID:23948738 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc51a |
solute carrier family 51 member A |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of SLC51A mRNA |
CTD |
PMID:23948738 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
increases expression |
ISO |
Oleanolic Acid results in increased expression of SLC51B mRNA; Oleanolic Acid results in increased expression of SLC51B protein |
CTD |
PMID:23948738 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of SLCO1A4 mRNA |
CTD |
PMID:23948738 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression multiple interactions |
ISO |
Oleanolic Acid results in decreased expression of SLCO1B2 protein Oleanolic Acid inhibits the reaction [Phalloidine results in increased expression of SLCO1B2 mRNA] |
CTD |
PMID:23948738 PMID:25280775 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO EXP |
Oleanolic Acid results in increased expression of SOD1 mRNA Oleanolic Acid inhibits the reaction [Ethanol results in decreased expression of SOD1 protein] |
CTD |
PMID:18706400 PMID:25111957 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Oleanolic Acid results in increased expression of SQSTM1 protein |
CTD |
PMID:35690101 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Oleanolic Acid promotes the reaction [NFE2L2 protein results in increased expression of SREBF1 mRNA] |
CTD |
PMID:28796629 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression multiple interactions |
ISO |
Oleanolic Acid results in increased expression of STAT3 mRNA Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] [Oleanolic Acid analog binds to Succinic Acid] which results in decreased expression of STAT3 mRNA |
CTD |
PMID:18706400 PMID:31306688 PMID:31401087 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions increases phosphorylation |
ISO |
U 0126 inhibits the reaction [Oleanolic Acid results in increased phosphorylation of STK11 protein] |
CTD |
PMID:36846903 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tet3 |
tet methylcytosine dioxygenase 3 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 mRNA]; Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of TET3 protein]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; TET3 protein inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:32894642 |
|
NCBI chr 4:115,867,412...115,964,433
Ensembl chr 4:115,871,265...115,964,193
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:21801858 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
Oleanolic Acid analog inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17922224 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Oleanolic Acid results in increased expression of TNF mRNA Oleanolic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Oleanolic Acid inhibits the reaction [Paraquat results in increased expression of TNF mRNA] Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of TNF protein] |
CTD |
PMID:18706400 PMID:21801858 PMID:22386814 PMID:31306688 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression |
ISO |
Oleanolic Acid results in increased expression of TNFRSF1B mRNA |
CTD |
PMID:18706400 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
decreases expression |
ISO |
Oleanolic Acid results in decreased expression of TOMM20 protein |
CTD |
PMID:35690101 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity decreases expression |
ISO |
Oleanolic Acid results in decreased activity of TOP1 protein Oleanolic Acid analog results in decreased expression of TOP1 protein |
CTD |
PMID:10860928 PMID:26612655 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases activity decreases expression |
ISO |
Oleanolic Acid results in decreased activity of TOP2A protein Oleanolic Acid analog results in decreased expression of TOP2A protein |
CTD |
PMID:10860928 PMID:26612655 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of TP53 mRNA |
CTD |
PMID:37345903 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of TRAP1 protein]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in decreased expression of TRAP1 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein]]; TRAP1 protein affects the reaction [Oleanolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein]] |
CTD |
PMID:33465424 |
|
NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects binding |
EXP |
Oleanolic Acid binds to TRPV1 protein |
CTD |
PMID:30496739 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Oleanolic Acid inhibits the reaction [HMGB1 protein results in increased expression of VCAM1 protein] |
CTD |
PMID:22386814 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
omaveloxolone analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein] |
CTD |
PMID:32410268 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased expression of GPT protein |
CTD |
PMID:32410268 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of LEP protein] |
CTD |
PMID:32410268 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects activity |
ISO |
rubiarbonone C affects the activity of CYP3A4 protein |
CTD |
PMID:30259074 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
decreases activity multiple interactions |
ISO |
rubiarbonone C results in decreased activity of CYP4F3 protein alternative form rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid] |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein] |
CTD |
PMID:20923188 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] |
CTD |
PMID:20923188 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased degradation of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20923188 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased secretion of NOS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:20923188 PMID:21397503 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:20923188 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:20923188 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases activity |
ISO |
soyasaponin I results in decreased activity of REN protein |
CTD |
PMID:19060406 PMID:20460744 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
St3gal4 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 4 |
decreases expression |
ISO |
soyasaponin I results in decreased expression of ST3GAL4 mRNA |
CTD |
PMID:15661230 |
|
NCBI chr 8:33,415,666...33,465,319
Ensembl chr 8:33,415,671...33,524,389
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:20923188 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
taraxasterol results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:35128947 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
taraxasterol results in increased cleavage of CASP3 protein |
CTD |
PMID:35128947 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
taraxasterol results in increased expression of CDH1 protein |
CTD |
PMID:35128947 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
taraxasterol results in decreased expression of CDH2 protein |
CTD |
PMID:35128947 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ctnna1 |
catenin alpha 1 |
increases expression |
ISO |
taraxasterol results in increased expression of CTNNA1 protein |
CTD |
PMID:35128947 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
taraxasterol results in increased cleavage of PARP1 protein |
CTD |
PMID:35128947 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases phosphorylation |
ISO |
taraxasterol results in decreased phosphorylation of PIK3R1 protein |
CTD |
PMID:35128947 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
taraxasterol results in decreased expression of VIM protein |
CTD |
PMID:35128947 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of ABCB1 mRNA; Ursolic Acid results in decreased expression of ABCB1 protein ABCB1 protein inhibits the reaction [Ursolic Acid results in increased susceptibility to Doxorubicin] |
CTD |
PMID:33009882 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Ursolic Acid results in increased phosphorylation of ACACA protein |
CTD |
PMID:24802810 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization decreases response to substance |
ISO |
Ursolic Acid results in increased localization of AIFM1 protein AIFM1 mutant form results in decreased susceptibility to Ursolic Acid |
CTD |
PMID:20630652 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Ursolic Acid results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:19344998 PMID:24802810 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [APP protein modified form results in decreased expression of RPT-3 protein]; Ursolic Acid inhibits the reaction [APP protein modified form results in increased susceptibility to Serotonin] |
CTD |
PMID:34902447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases activity |
ISO |
Ursolic Acid results in increased activity of BAK1 protein |
CTD |
PMID:20630652 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of BAX protein Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein] |
CTD |
PMID:16012738 PMID:24051192 PMID:36587836 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions increases phosphorylation |
ISO |
Ursolic Acid results in decreased expression of BCL2 mRNA; Ursolic Acid results in decreased expression of BCL2 protein [Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein] |
CTD |
PMID:16012738 PMID:24802810 PMID:28868958 PMID:36587836 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein] |
CTD |
PMID:24802810 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO |
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein Ursolic Acid results in increased activity of CASP3 protein Ursolic Acid results in increased expression of CASP3 protein |
CTD |
PMID:16012738 PMID:19329757 PMID:20005942 PMID:24051192 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Ursolic Acid results in increased activity of CASP7 protein |
CTD |
PMID:19329757 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Ursolic Acid results in increased activity of CASP8 protein |
CTD |
PMID:20005942 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Ursolic Acid results in increased activity of CAT protein |
CTD |
PMID:24051192 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CCND1 mRNA; Ursolic Acid results in decreased expression of CCND1 protein |
CTD |
PMID:24566423 PMID:24802810 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CCND3 protein |
CTD |
PMID:24802810 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CCNE1 protein |
CTD |
PMID:24802810 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CDK4 protein |
CTD |
PMID:24802810 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Ursolic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:24802810 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Ursolic Acid results in increased expression of CDKN1B protein |
CTD |
PMID:24802810 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
Ursolic Acid results in increased phosphorylation of and results in increased degradation of CTNNB1 protein |
CTD |
PMID:24566423 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Ursolic Acid affects the localization of CYCS protein |
CTD |
PMID:16012738 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions decreases activity |
ISO |
Ursolic Acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] Ursolic Acid results in decreased activity of CYP2C19 protein |
CTD |
PMID:15043991 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased expression of EDN1 protein] |
CTD |
PMID:27567547 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] |
CTD |
PMID:26100520 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Ursolic Acid results in increased phosphorylation of EIF2AK3 protein EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of EIF4EBP1 protein |
CTD |
PMID:24802810 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases activity |
ISO |
Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of ERN1 protein] Ursolic Acid results in increased activity of ERN1 protein |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased activity of GPT protein] |
CTD |
PMID:27567547 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of HSPA5 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of ICAM1 mRNA; Ursolic Acid results in decreased expression of ICAM1 protein |
CTD |
PMID:20005942 PMID:21539908 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; [Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein] |
CTD |
PMID:37019307 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA] Ursolic Acid results in decreased expression of IL6 protein |
CTD |
PMID:20869956 PMID:23835587 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]] |
CTD |
PMID:23835587 PMID:26100520 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Ursolic Acid results in increased expression of LEP protein |
CTD |
PMID:20869956 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of LONP1 protein] |
CTD |
PMID:36587836 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:27274199 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:27274199 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:27274199 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:27274199 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO EXP |
[Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein] Ursolic Acid results in decreased expression of MMP2 mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein] |
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO EXP |
Ursolic Acid results in decreased expression of MMP9 mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein] [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] |
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA |
CTD |
PMID:37019307 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases phosphorylation |
ISO |
ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:24802810 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKB1 protein] |
CTD |
PMID:23835587 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Ursolic Acid analog results in decreased phosphorylation of and results in increased expression of NFKBIA protein |
CTD |
PMID:26134000 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of NOS2 protein |
CTD |
PMID:24051192 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased expression of NOS3 protein] |
CTD |
PMID:27567547 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Ursolic Acid results in increased cleavage of PARP1 protein |
CTD |
PMID:16012738 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion multiple interactions |
ISO |
Ursolic Acid results in decreased secretion of PLAU protein [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of PLAU protein |
CTD |
PMID:36191607 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of PLAUR protein [Ursolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid] results in increased secretion of and results in decreased expression of PLAUR protein |
CTD |
PMID:36191607 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein] 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein] |
CTD |
PMID:27274199 PMID:37019307 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]] |
CTD |
PMID:23835587 PMID:26100520 PMID:26513295 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of PTPN1 protein |
CTD |
PMID:27085377 PMID:29175190 PMID:30160205 PMID:36933777 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
Ursolic Acid analog results in decreased expression of RELA mRNA; Ursolic Acid analog results in decreased expression of RELA protein |
CTD |
PMID:26134000 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of RPS6KB1 protein |
CTD |
PMID:24802810 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of SIGMAR1 protein Ursolic Acid inhibits the reaction [bardoxolone methyl results in decreased expression of SIGMAR1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of SIGMAR1 protein] |
CTD |
PMID:36587836 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]] |
CTD |
PMID:26100520 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]] |
CTD |
PMID:26100520 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of TGFB1 protein |
CTD |
PMID:21539908 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein] 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein] |
CTD |
PMID:27274199 PMID:37019307 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of TNF protein |
CTD |
PMID:24051192 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of TOP1 protein |
CTD |
PMID:10860928 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of TOP2A protein |
CTD |
PMID:10860928 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of VEGFA protein |
CTD |
PMID:24051192 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|